There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cullinan Management (CGEM – Research Report), Intellia Therapeutics (NTLA – Research Report) and Nkarta (NKTX – Research Report) with bullish sentiments.
Cullinan Management (CGEM)
Leerink Partners analyst Andrew Berens maintained a Buy rating on Cullinan Management on November 7 and set a price target of $28.00. The company’s shares closed last Friday at $16.02.
According to TipRanks.com, Berens is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.9% and a 39.8% success rate. Berens covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, Arvinas Holding Company, and Compass Therapeutics.
Cullinan Management has an analyst consensus of Strong Buy, with a price target consensus of $32.38, representing a 104.4% upside. In a report issued on November 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $28.00 price target.
See the top stocks recommended by analysts >>
Intellia Therapeutics (NTLA)
In a report issued on November 7, Mani Foroohar from Leerink Partners reiterated a Buy rating on Intellia Therapeutics, with a price target of $51.00. The company’s shares closed last Friday at $16.73, close to its 52-week low of $13.95.
According to TipRanks.com, Foroohar is ranked 0 out of 5 stars with an average return of -6.7% and a 41.1% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Arrowhead Pharmaceuticals, and Recursion Pharmaceuticals.
Currently, the analyst consensus on Intellia Therapeutics is a Strong Buy with an average price target of $55.00, which is a 242.7% upside from current levels. In a report issued on October 25, Evercore ISI also assigned a Buy rating to the stock with a $60.00 price target.
Nkarta (NKTX)
In a report issued on November 8, Daina Graybosch from Leerink Partners maintained a Buy rating on Nkarta. The company’s shares closed last Friday at $3.19, close to its 52-week low of $1.90.
According to TipRanks.com, Graybosch ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -11.7% and a 34.9% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Turnstone Biologics Corp., Werewolf Therapeutics, and Bolt Biotherapeutics.
Nkarta has an analyst consensus of Strong Buy, with a price target consensus of $15.67, implying a 376.3% upside from current levels. In a report issued on November 8, TD Cowen also assigned a Buy rating to the stock.
Read More on CGEM: